FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Apple Restores Telegram to App Store After Content Policy Violation 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
INDIAN WELLS, Calif., April 06, 2018 -- Nova Oculus Partners, LLC today issued the following statement from its founder Peter Pocklington:
I am extremely proud of what we have accomplished in a short time.
I founded Nova Oculus four years ago because I firmly believe the microcurrent electro-therapy technology behind our medical device successfully mitigates symptoms of the dry version of Age-Related Macular Degeneration.
I personally suffer from AMD, and my experience with early prototypes of our device attests to its promise. And I’m not the only one.
We have a blue-ribbon team of professionals leading our efforts to bring Nova Oculus to market. We also assembled a medical advisory board that includes some of the leading optometric professionals in the United States to develop a plan to earn FDA approval and widespread commercialization in the U.S.
Our device is currently being considered for a medical license by the Canadian government regulator, Health Canada, for commercialization in that country. It also is undergoing a clinical trial with patient test groups in Calgary, Canada.
Our Nova Oculus device has been certified by the International Organization of Standardization (ISO) as complying with quality control and safety in its development, and by the International Electrotechnical Commission, which gave its approval for the device’s electrical safety. These certifications pave the way for global regulatory approvals for Nova Oculus.
The real story of Nova Oculus is our promising technology, our brilliant team and our achievements. This created credibility for the company and faith by investors.
The SEC’s announcement was a laundry list of misguided accusations based on unrelated items of dubious interest. We intend to vigorously defend our reputation. We will fight to bring the Nova Oculus medical device to market. It’s the right thing to do.
AMD has no cure. It is the leading cause of blindness in North America. More than 14 million people suffer from this affliction — a figure that is expected to double as baby boomers age.
Our goal is unwavering. We will do all we can to restore sight to people who would otherwise not have any.
That is my promise to you.
Peter Pocklington
Founder, Nova Oculus
Contact:
Sonya Bucher
[email protected]
(323) 399-1166
